title: Association of busulfan and cyclophosphamide conditioning with sleep disorders after hematopoietic stem cell transplantation.
abstract: New indications and conditioning regimens for hematopoietic stem cell transplantation (HSCT) have emerged in the last 10 years. Previous studies have shown the association of HSCT with late effects such as sleep disorders. The aim of this study was to determine the prevalence and factors associated with sleep disorders following HSCT in a population considering these new trends. Sixty-one individuals 1-10 years after allogeneic HSCT were surveyed using the DSM-IV-TR criteria for sleep disorders. Factors related to conditioning and graft-versus-host disease were collected from medical records. A prevalence of sleep disorders of 26.2% was found. Busulfan-cyclophosphamide conditioning was an independent risk factor in a multivariate analysis (relative risk, RR: 3.74, 95% CI: 1.1-12.6; p = 0.03), which also included sex (RR: 2.37, 95% CI: 1.0-5.7; p = 0.05) and age (RR: 1.03, 95% CI: 0.99-1.07; p = 0.11). Sleep disorders were frequent following HSCT. Patients who were treated with busulfan-cyclophosphamide had a higher risk of developing this complication. Female sex was also possibly a risk factor.
authors.affiliation: Division of Internal Medicine, Hospital de Clínicas de Porto Alegre, Porto Alegre, Rio Grande do Sul, Brazil. gfaulhaber@hcpa.ufrgs.br
authors.forename: Gustavo Adolpho Moreira
authors.initials: GA
authors.lastname: Faulhaber
authors.forename: Tania W
authors.initials: TW
authors.lastname: Furlanetto
authors.forename: Claudia C
authors.initials: CC
authors.lastname: Astigarraga
authors.forename: Humberto Luiz
authors.initials: HL
authors.lastname: Moser Filho
authors.forename: Angela Paula
authors.initials: AP
authors.lastname: Paludo
authors.forename: Lucia M R
authors.initials: LM
authors.lastname: Silla
mesh_terms: D000328:Adult; D002066:Busulfan / Q000009:adverse effects*; D003520:Cyclophosphamide / Q000009:adverse effects*; D005260:Female; D006086:Graft vs Host Disease / Q000453:epidemiology; D019337:Hematologic Neoplasms / Q000453:epidemiology / Q000628:therapy*; D018380:Hematopoietic Stem Cell Transplantation / Q000706:statistics & numerical data; D006801:Humans; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D019653:Myeloablative Agonists / Q000009:adverse effects; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D012893:Sleep Wake Disorders / Q000139:chemically induced* / Q000453:epidemiology; D019172:Transplantation Conditioning / Q000009:adverse effects*
chemical_list: D019653:Myeloablative Agonists; D003520:Cyclophosphamide; D002066:Busulfan